ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca2+ -signalling dysregulation or toxicity in pancreatic acinar cells.

MLA

Jakubowska, Monika A., et al. “ABT-199 (Venetoclax), a BH3-Mimetic Bcl-2 Inhibitor, Does Not Cause Ca2+ -Signalling Dysregulation or Toxicity in Pancreatic Acinar Cells.” British Journal of Pharmacology, vol. 176, no. 22, Nov. 2019, pp. 4402–15. EBSCOhost, https://doi.org/10.1111/bph.14505.

APA

Jakubowska, M. A., Kerkhofs, M., Martines, C., Efremov, D. G., Gerasimenko, J. V., Gerasimenko, O. V., Petersen, O. H., Bultynck, G., Vervliet, T., & Ferdek, P. E. (2019). ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca2+ -signalling dysregulation or toxicity in pancreatic acinar cells. British Journal of Pharmacology, 176(22), 4402–4415. https://doi.org/10.1111/bph.14505

Chicago

Jakubowska, Monika A, Martijn Kerkhofs, Claudio Martines, Dimitar G Efremov, Julia V Gerasimenko, Oleg V Gerasimenko, Ole H Petersen, Geert Bultynck, Tim Vervliet, and Pawel E Ferdek. 2019. “ABT-199 (Venetoclax), a BH3-Mimetic Bcl-2 Inhibitor, Does Not Cause Ca2+ -Signalling Dysregulation or Toxicity in Pancreatic Acinar Cells.” British Journal of Pharmacology 176 (22): 4402–15. doi:10.1111/bph.14505.